# Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas

> **NCT06687681** · PHASE2 · RECRUITING · sponsor: **Marzieh Ebrahimi** · enrollment: 40 (estimated)

## Conditions studied

- Glioma Glioblastoma Multiforme
- High Grade Glioma (III or IV)

## Interventions

- **BIOLOGICAL:** NK cell therapy

## Key facts

- **NCT ID:** NCT06687681
- **Lead sponsor:** Marzieh Ebrahimi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-25
- **Primary completion:** 2025-11-25
- **Final completion:** 2027-11-25
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06687681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06687681, "Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06687681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*